R&D | January 21, 2026
Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
Subscribe To Our Newsletter & Stay Updated
